Elicio Therapeutics Inc. Common Stock (ELTX)
Stock · NASDAQ · Health Care
$1.56as of 10/16/2026
Price chart
Active signals
ELTX Signal Track Record
How signals performed across all stocks →What ELTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | -3.3% | 47% | September 16, 2026 |
| Bollinger Band Breakout | 26 | -3.7% | 42% | June 1, 2026 |
| Bollinger Band Breakdown | 21 | -7.4% | 33% | August 31, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -1.6% | 45% | May 8, 2026 |
| Any 20-session window (baseline) | -3.2% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ELTX
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide trea…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 33
- Website
- elicio.com/
Fundamentals
- 1-day range
- $1.77$1.86
- Market cap
- $72.28M
- P/E (trailing)
- —
- P/E (forward)
- -1.05
- EPS (trailing)
- $-2.18
- Dividend yield
- —
- Beta
- 1.65
- Avg. volume
- 318.5K
Forecasts
3 analyst ratings
Elicio Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ELTXElicio Therapeutics Inc. Common Stock$1.56▼ 12.36%Market cap $72.28MP/E —$1.71$16
- ACRVAcrivon Therapeutics Inc. Common Stock$1.64▼ 6.82%Market cap $72.33MP/E —$1.27$3.56
- CYPHCypherpunk Technologies Inc. Common Stock$2.57▼ 14.90%Market cap $71.74MP/E —$0.393$4.19
- SPROSpero Therapeutics Inc. Common Stock$1.1▼ 2.65%Market cap $73.53MP/E 8.91$1.08$3.08
- CTORCitius Oncology Inc. Common Stock$0.768▲ 2.95%Market cap $70.67MP/E —$0.491$2.25
- ACETAdicet Bio Inc. Common Stock$4.57▼ 11.09%Market cap $74.13MP/E —$4.8$17.04
- TLPHTalphera Inc. Common Stock$1.08▲ 0.93%Market cap $74.22MP/E —$0.6866$1.57
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ELTX Elicio Therapeutics Inc. Common Stock | $72.28M | — | $1.56 | ▼ 12.36% | $1.71$16 |
| ACRV Acrivon Therapeutics Inc. Common Stock | $72.33M | — | $1.64 | ▼ 6.82% | $1.27$3.56 |
| CYPH Cypherpunk Technologies Inc. Common Stock | $71.74M | — | $2.57 | ▼ 14.90% | $0.393$4.19 |
| SPRO Spero Therapeutics Inc. Common Stock | $73.53M | 8.91 | $1.1 | ▼ 2.65% | $1.08$3.08 |
| CTOR Citius Oncology Inc. Common Stock | $70.67M | — | $0.768 | ▲ 2.95% | $0.491$2.25 |
| ACET Adicet Bio Inc. Common Stock | $74.13M | — | $4.57 | ▼ 11.09% | $4.8$17.04 |
| TLPH Talphera Inc. Common Stock | $74.22M | — | $1.08 | ▲ 0.93% | $0.6866$1.57 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- B. Riley Securities Maintains Buy on Elicio Therapeutics, Lowers Price Target to $8benzinga · 9/24/2026
- Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026Yahoo · 9/24/2026
- B. Riley Securities Maintains Buy on Elicio Therapeutics, Lowers Price Target to $8Benzinga · 9/24/2026
Insider Activity
Insider Actions →- Yekaterina Chudnovsky · August 31, 2026 · Grant21.8K
- Ashe Carol Gail · August 31, 2026 · Grant21.8K
- Nissenson Allen · August 31, 2026 · Grant21.8K
- Jay Venkatesan · August 31, 2026 · Grant21.8K
- Karen J. Wilson · August 31, 2026 · Grant21.8K
- ADAMS JULIAN · August 31, 2026 · Grant21.8K
- RUFFOLO ROBERT R · August 31, 2026 · Grant21.8K
- Peter DeMuth · July 16, 2026 · Grant52.8K
- Robert Connelly · July 16, 2026 · Grant186.9K
- Preetam Shah · July 16, 2026 · Grant60.8K
- Christopher Haqq · July 16, 2026 · Grant64.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 3.06M
- Total value held
- $32.47M
- Institutional holders
- 47
- Unknown630.9K
- Unknown518.6K
- Unknown373.8K
- Unknown244.8K
- Unknown135.2K
- Unknown121.6K
- Unknown115.6K
- Unknown92.8K
- Unknown78.1K
- Unknown74.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
ELTX presents Phase 2 data at ESMO Congress; B. Riley lowers target
Elicio Therapeutics disclosed that its late‑breaking Phase 2 AMPLIFY‑7P results have been selected for an oral presentation at the upcoming ESMO Congress 2026. The selection highlights ongoing clinical progress for the company's oncology program. Separately, B. Riley Securities kept its coverage on ELTX but reduced its price target to $8, reflecting a more cautious outlook.
ELTX presents Phase 2 data at ESMO Congress; B. Riley lowers target. Elicio Therapeutics disclosed that its late‑breaking Phase 2 AMPLIFY‑7P results have been selected for an oral presentation at the upcoming ESMO Congress 2026. The selection highlights ongoing clinical progress for the company's oncology program. Separately, B. Riley Securities kept its coverage on ELTX but reduced its price target to $8, reflecting a more cautious outlook.